Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.55 |
| ▸ | APP | P05067 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477113 | 0.88 | ABCG2 (0.59) | CYP1A1CYP1A2CYP1B1APPABCG2 | |
| SCHEMBL29085617 | 0.82 | METAP1 (0.48) | ABCG2BACE1 | |
| SCHEMBL1395347 | 0.78 | CYP1A1 (0.77) | CYP1A1CYP1A2CYP1B1ABCG2ADORA2A | |
| SCHEMBL29593101 | 0.78 | CYP1A1 (0.77) | CYP1A1CYP1A2CYP1B1ABCG2ADORA2A | |
| Hydrochloric Acid SCHEMBL29281621 | 0.77 | CYP1A1 (0.77) | CYP1A1CYP1A2CYP1B1ABCG2ADORA2A | |
| SCHEMBL13300265 | 0.76 | APP (0.47) | CYP1A1CYP1A2CYP1B1APPABCG2 | |
| SCHEMBL14529287 | 0.75 | CYP1A1 (0.77) | CYP1A1CYP1A2CYP1B1ABCG2ADORA2A | |
| SCHEMBL2297357 | 0.75 | CYP1A2 (0.58) | CYP1A1CYP1A2CYP1B1APPABCG2 | |
| SCHEMBL28197250 | 0.74 | CYP1A1 (0.71) | CYP1A1CYP1A2CYP1B1ABCG2ADORA2A | |
| SCHEMBL22988235 | 0.74 | ADORA3 (0.51) | CYP1A2ADORA2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | CYP1A1 1843/4885CYP1A2 892/4885CYP1B1 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.